Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Files An 8-K Regulation FD Disclosure
Item 7.01

Syros Pharmaceuticals, Inc. Exhibit
EX-99.1 2 d651281dex991.htm EX-99.1 EX-99.1 An Expression Makes a World of Difference December 2,…
To view the full exhibit click here

About Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.